Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Fagan

Showing results (121-130 of 279) with videos related to

Pageof 28
Sort By:
Human Molecular Genetics|July 24, 2012
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's diseaseCarlos Cruchaga, John S K Kauwe, Petra Nowotny, et al.
JAMA Neurology|January 8, 2019
Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseJohn C Morris, Suzanne E Schindler, Lena M McCue, et al.
BMJ Open|September 16, 2021
Falls: a marker of preclinical Alzheimer disease: a cohort study protocolRebecca M Bollinger, Audrey Keleman, Regina Thompson, et al.
Molecular Neurodegeneration|April 14, 2007
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphismsSuzanne E Wahrle, Aarti R Shah, Anne M Fagan, et al.
Neuroimage|December 20, 2016
In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imagingYue Zhao, Marcus E Raichle, Jie Wen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 13, 2018
Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkersSarah H Stout, Ganesh M Babulal, Chunyu Ma, et al.
Journal of Alzheimer'S Disease : JAD|December 13, 2021
Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tisssue Atrophy in Early Alzheimer's DiseaseSatya V V N Kothapalli, Tammie L Benzinger, Andrew J Aschenbrenner, et al.
Alzheimer'S Research & Therapy|September 19, 2015
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohortMaartje I Kester, Charlotte E Teunissen, Courtney Sutphen, et al.
Brain : a Journal of Neurology|September 14, 2017
Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levelsYo-El S Ju, Sharon J Ooms, Courtney Sutphen, et al.
Neurology|April 12, 2013
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years laterCatherine M Roe, Anne M Fagan, Elizabeth A Grant, et al.
Pageof 28

Showing results (121-130 of 279) with videos related to

Sort By:
Pageof 28
Human Molecular Genetics|July 24, 2012
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's diseaseCarlos Cruchaga, John S K Kauwe, Petra Nowotny, et al.
JAMA Neurology|January 8, 2019
Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseJohn C Morris, Suzanne E Schindler, Lena M McCue, et al.
BMJ Open|September 16, 2021
Falls: a marker of preclinical Alzheimer disease: a cohort study protocolRebecca M Bollinger, Audrey Keleman, Regina Thompson, et al.
Molecular Neurodegeneration|April 14, 2007
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphismsSuzanne E Wahrle, Aarti R Shah, Anne M Fagan, et al.
Neuroimage|December 20, 2016
In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imagingYue Zhao, Marcus E Raichle, Jie Wen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 13, 2018
Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkersSarah H Stout, Ganesh M Babulal, Chunyu Ma, et al.
Journal of Alzheimer'S Disease : JAD|December 13, 2021
Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tisssue Atrophy in Early Alzheimer's DiseaseSatya V V N Kothapalli, Tammie L Benzinger, Andrew J Aschenbrenner, et al.
Alzheimer'S Research & Therapy|September 19, 2015
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohortMaartje I Kester, Charlotte E Teunissen, Courtney Sutphen, et al.
Brain : a Journal of Neurology|September 14, 2017
Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levelsYo-El S Ju, Sharon J Ooms, Courtney Sutphen, et al.
Neurology|April 12, 2013
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years laterCatherine M Roe, Anne M Fagan, Elizabeth A Grant, et al.
Pageof 28